Ann Pharmacother 2016 Apr;50(4):336
Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib.
Malkan UY, Gunes G, Etgul S, Aslan T, Aydin S, Haznedaroglu IC.
href="/pubmed/?term=Malkan%20UY%5BAuthor%5D&cauthor=true&cauthor_uid=26861992">Malkan UY,
Gunes G
,
Etgul S
,
Aslan T
,
Aydin S
,
Haznedaroglu IC
.
Comment on
Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib.
[Ann Pharmacother. 2015]
Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.
[Ann Pharmacother. 2016]
PMID:
26861992
DOI:
10.1177/1060028016629981
[PubMed]
Share
Publication Types
Publication Types
Comment
Letter
LinkOut - more resources
Full Text Sources
HighWire - PDF
PubMed Commons home
PubMed Commons
0
comments
How to join PubMed Commons
How to cite this comment:
Supplemental Content
Full text links
26861992[uid]
Search
See more...
You are here:
NCBI
>
Literature
> PubMed
Write to the Help Desk